⚠ Evidence warning: Clinical trials or other evidence do not support the claim that people with darker skin or a working MC1R receptor respond better to phenylalanine plus ultraviolet A, and that added nutrients (copper, vitamin D3, vitamins C and E, alpha-lipoic acid, L-tyrosine) support response rates and reduce relapse. This page keeps it as a report of what people, websites or other media say.

Phenylalanine for Skin Pigmentation and Vitiligo

Skin Pigmentation — scientific infographic poster

The same biochemical pathway that converts phenylalanine to tyrosine to L-DOPA also delivers the substrate for melanin — the pigment that gives skin, hair, and eyes their color and that protects the genome of every superficial skin cell from ultraviolet damage. In specialized melanocyte cells of the epidermis, tyrosine is oxidized by the copper-dependent enzyme tyrosinase to form DOPA and then dopaquinone, which polymerizes through a complex series of reactions into eumelanin (brown-black) or pheomelanin (red-yellow). When this pathway fails locally — as it does in the autoimmune disease vitiligo, where melanocytes are destroyed by the patient's own immune system — supplying additional substrate can support the survival and re-pigmentation activity of remaining melanocytes. The Cormane 1985 study and the Antoniou 1989 study reported that oral phenylalanine combined with ultraviolet A (UVA) exposure can produce repigmentation in vitiligo patients (in the Cormane study mainly in skin areas lying over subcutaneous fat). The mechanism, the evidence, and the protocols the studies used are the subject of this deep-dive.


Table of Contents

  1. Melanin Biology and the Tyrosinase Reaction
  2. Eumelanin vs Pheomelanin and the MC1R Determinant
  3. Melanocytes — Architecture and Function
  4. Vitiligo — The Autoimmune Pigment Loss
  5. The Cormane 1985 Trial
  6. The Antoniou 1989 Trial with Ultraviolet A
  7. Oral vs Topical Phenylalanine Protocols
  8. Response Patterns and Patient Selection
  9. Comparison to Khellin (KUVA) Therapy
  10. Comparison to Tacrolimus and Calcineurin Inhibitors
  11. Combination Protocols and Adjunct Nutrients
  12. PKU and the Lighter Pigmentation Connection
  13. Cautions and Contraindications
  14. Key Research Papers
  15. Connections
  16. Featured Videos

Melanin Biology and the Tyrosinase Reaction

Melanin is the principal pigment of human skin, hair, and the iris of the eye. It absorbs ultraviolet radiation across a broad spectrum, dissipates the absorbed energy as heat, scavenges reactive oxygen species, and provides physical protection to the genome of underlying keratinocyte stem cells. Without adequate melanin, skin is vulnerable to ultraviolet-induced DNA damage, sunburn, accelerated photoaging, and dramatically increased risk of skin cancer including melanoma.

The biosynthesis of melanin begins with tyrosine. The first and rate-limiting step is performed by tyrosinase (EC 1.14.18.1), a copper-containing enzyme that catalyzes two sequential reactions:

  1. Tyrosine + O2 → L-DOPA (3,4-dihydroxyphenylalanine). The hydroxylation of tyrosine, requiring molecular oxygen and the two copper atoms at the tyrosinase active site.
  2. L-DOPA + O2 → dopaquinone. The further oxidation of L-DOPA to a reactive quinone.

Dopaquinone is then routed through one of two divergent pathways depending on the local cellular environment:

The same precursor pathway that supplies dopamine and the catecholamines also supplies melanin. The branch point is tissue-specific: in catecholamine-producing neurons, the L-DOPA produced by tyrosine hydroxylase is decarboxylated to dopamine by aromatic L-amino acid decarboxylase. In melanocytes, the L-DOPA produced by tyrosinase is oxidized to dopaquinone and polymerized to melanin. The phenylalanine and tyrosine that feed both pathways are the same dietary pool.

Back to Table of Contents

Eumelanin vs Pheomelanin and the MC1R Determinant

Human skin and hair color is determined principally by the ratio of eumelanin to pheomelanin. Eumelanin dominates in dark skin and dark hair; pheomelanin dominates in fair skin and red hair. The mixture is determined by the activity of the melanocortin 1 receptor (MC1R) on the melanocyte surface, which is activated by alpha-melanocyte-stimulating hormone (alpha-MSH).

The relationships are:

The clinical relevance for phenylalanine supplementation: increasing substrate availability does not change the eumelanin/pheomelanin ratio. A patient with low MC1R activity who responds to phenylalanine supplementation produces more pheomelanin, not more eumelanin. The protective effect against ultraviolet damage is therefore better in patients with functional MC1R who can route the additional substrate to eumelanin. This explains some of the inter-patient variability in vitiligo treatment response — patients with darker constitutive skin tone tend to respond better to phenylalanine + ultraviolet A repigmentation protocols than patients with very fair skin and red hair phenotype.

Back to Table of Contents

Melanocytes — Architecture and Function

Melanocytes are the specialized dendritic cells of the basal epidermis that produce melanin. They constitute approximately 5 to 10 percent of basal epidermal cells. Each melanocyte projects long dendritic processes that contact approximately 36 surrounding keratinocytes, forming the "epidermal melanin unit." Melanin synthesized within the melanocyte's melanosome organelles is packaged and transferred to the surrounding keratinocytes through a phagocytic process, ultimately positioning the melanin granules over the nuclei of the keratinocytes to shield the keratinocyte DNA from ultraviolet damage.

Melanocytes are unusual cells in several ways relevant to vitiligo:

The reservoir of melanocyte precursors that can repopulate depigmented areas comes from two sources: the outer root sheath of hair follicles (the principal source for most skin) and migratory melanoblasts from immediately adjacent normally-pigmented skin. The hair follicle reservoir explains the perifollicular pattern of repigmentation that is the typical clinical sign of successful vitiligo treatment — pigment spots appear first around hair follicles and gradually coalesce.

Back to Table of Contents

Vitiligo — The Autoimmune Pigment Loss

Vitiligo is an acquired depigmentation disorder affecting approximately 1 percent of the global population. It is characterized by patches of complete pigment loss in previously normally-pigmented skin, typically appearing in young adulthood, often initially on sun-exposed areas (face, hands) or in areas of friction (elbows, knees, axillae) or genital regions. The course is variable: some patients have stable patches that never extend; others have steadily progressive depigmentation that can eventually involve most of the body surface.

The current consensus on pathophysiology is that vitiligo is an autoimmune disease in which CD8+ cytotoxic T cells specifically destroy melanocytes. The autoantigens include tyrosinase, TRP1, TRP2, gp100, and other melanocyte-specific proteins. The trigger for autoimmunity is multifactorial — genetic susceptibility (multiple loci including NLRP1, PTPN22, TYR), oxidative stress within melanocytes producing autoantigens through protein damage, environmental triggers (Koebner phenomenon — new patches appearing at sites of skin trauma), and possible cross-reactivity with infectious antigens.

The relevant subtypes for treatment planning are:

Standard medical treatments include topical corticosteroids (high-potency for non-facial, mid-potency for facial), topical calcineurin inhibitors (tacrolimus, pimecrolimus — particularly useful for facial and intertriginous areas where steroids are problematic), phototherapy (narrowband ultraviolet B (UVB) is current standard, sometimes combined with topical agents), excimer laser for localized patches, JAK inhibitors (recently approved ruxolitinib cream), and in advanced or stable disease, surgical melanocyte transplantation. Oral and topical phenylalanine combined with ultraviolet A exposure occupies a complementary niche for patients seeking nutritional adjunct therapy and for facial repigmentation maintenance.

Back to Table of Contents

The Cormane 1985 Trial

The classical clinical demonstration of phenylalanine for vitiligo was published by R.H. Cormane and colleagues in 1985 in Archives of Dermatological Research. Patients took oral L-phenylalanine at 50 mg/kg body weight, which raised the phenylalanine level in their blood. Because the blood level peaks between 30 and 45 minutes after the dose, the ultraviolet A exposure was given at that time.

The Cormane results, as the published summary reports them:

The published summary gives no patient count and describes no control group, so the natural fluctuation of vitiligo and placebo and observer biases may have contributed to the results. The mechanism proposed was that oral phenylalanine raises plasma and intra-melanocyte tyrosine, providing substrate for melanin synthesis, while the ultraviolet A exposure stimulates melanocyte proliferation and increases tyrosinase activity. The combined effect was hypothesized to overcome the substrate limitation that constrains remaining melanocytes in vitiligous skin.

The Cormane 1985 paper is significant as the first published demonstration of phenylalanine for vitiligo and remains the most-cited reference for the approach. Subsequent controlled trials have produced more modest response rates but generally confirm that the protocol produces meaningful repigmentation in a subset of patients.

Back to Table of Contents

The Antoniou 1989 Trial with Ultraviolet A

C. Antoniou and colleagues published a follow-up study in 1989 in the International Journal of Dermatology. Twenty-one patients with vitiligo were divided into two groups. Eleven took oral L-phenylalanine at 100 mg/kg body weight with ultraviolet A exposure. Ten took the same oral dose with ultraviolet A exposure and, in addition, applied a cream containing 10% L-phenylalanine to the white patches.

Antoniou results:

Later studies reported results in the same direction:

Face and trunk are described as responding best and hands and feet least. Multiple meta-analyses of vitiligo treatments have included phenylalanine + ultraviolet A as one of the established options, generally placing it as a second-line or adjunctive treatment after topical corticosteroids, topical calcineurin inhibitors, and narrowband ultraviolet B phototherapy.

Back to Table of Contents

Oral vs Topical Phenylalanine Protocols

Two delivery routes have been studied:

The Cormane study used oral dosing; the Antoniou study gave the oral dose to both groups and added a 10% phenylalanine cream in one of them. Topical-only protocols have been studied with less rigor but have shown comparable response rates with smaller magnitude effects per treated area, presumably because topical penetration is limited. In the small Antoniou study, oral plus topical treatment gave better results than oral treatment alone.

What the published protocols used:

  1. Oral L-phenylalanine 50 mg/kg body weight in the Cormane study and 100 mg/kg in the Antoniou study. Siddiqui and colleagues (1994) found that a higher dose raised blood phenylalanine but did not improve results, and put the best dose below 50 mg/kg a day
  2. Ultraviolet A exposure timed to the peak blood level: 30 to 45 minutes after the oral dose in the Cormane study (Siddiqui measured the peak at 30 to 60 minutes)
  3. Practitioners describe ultraviolet A exposure starting at 3 to 5 minutes and building gradually to 15 to 30 minutes per session, twice weekly
  4. Courses of 4 months (Cormane, 32 treatments), 6 months (Siddiqui double-blind trial) and 18 months (Siddiqui open trial)
  5. A cream containing 10 percent phenylalanine on the white patches, added to the oral dose in the better-performing Antoniou group
  6. Practitioners describe sunscreen on normally pigmented skin, because tanning there increases the contrast with the white patches
  7. Some protocols add vitamin and antioxidant cofactors throughout treatment (see below)

Back to Table of Contents

Response Patterns and Patient Selection

The clinical pattern of vitiligo response to phenylalanine + ultraviolet A is characteristic and predictable:

Patient features associated with better response:

Patient features associated with poorer response:

How long the pigment lasts. A German follow-up study (Greiner and colleagues, 1994) looked back at 41 people treated with phenylalanine plus ultraviolet A about 5 years earlier. Twenty-five could be examined: 11 of them (44%) had lasting repigmentation, but 16 (64%) had lost pigment again during or after treatment. Signs that went with better repigmentation were vitiligo covering less than 25% of the body, onset before age 21, a generalized and symmetrical pattern, and a long course of ultraviolet therapy. None of the patients had long-term side effects, and 52% were satisfied with the treatment and would repeat it.

Back to Table of Contents

Comparison to Khellin (KUVA) Therapy

Khellin is a furanochromone extracted from the seeds of the Mediterranean plant Ammi visnaga (toothpick weed). It has been used in combination with ultraviolet A exposure (the KUVA protocol) as an alternative to traditional psoralen + UVA (PUVA) therapy for vitiligo. The mechanism is similar to psoralens — photo-activation produces reactive intermediates that stimulate melanocyte proliferation and tyrosinase activity — but khellin lacks the carcinogenic potential of the linear psoralens that limit long-term PUVA use.

Comparison with phenylalanine + ultraviolet A:

For patients seeking the most evidence-based current options, narrowband ultraviolet B phototherapy (twice weekly for 6 to 12 months) has displaced both KUVA and phenylalanine + ultraviolet A as the preferred first-line phototherapy because of comparable efficacy and superior safety. Phenylalanine + ultraviolet A retains a niche for patients who prefer a nutritional adjunct, who have limited access to narrowband ultraviolet B, or who want to combine oral phenylalanine with other phototherapy.

Back to Table of Contents

Comparison to Tacrolimus and Calcineurin Inhibitors

Topical tacrolimus 0.1 percent ointment (and pimecrolimus 1 percent cream) are calcineurin inhibitors originally developed for atopic dermatitis that have become first-line treatments for vitiligo, particularly facial and intertriginous involvement. The mechanism is local immunosuppression that reduces the CD8+ T-cell attack on remaining melanocytes, allowing them to survive and resume pigment production.

Comparison with phenylalanine:

The two are complementary rather than competing. Some practitioners describe a combined approach for facial vitiligo: topical tacrolimus 0.1 percent twice daily (the immunosuppressive component) with oral phenylalanine 50 mg/kg daily and twice-weekly ultraviolet A exposure (the substrate and proliferative components), with topical corticosteroids added briefly during actively spreading disease before longer-term maintenance with tacrolimus + phenylalanine.

Ruxolitinib cream, a newer option. Ruxolitinib blocks the Janus kinase 1 and 2 enzymes (a JAK inhibitor). In two phase 3 trials published in 2022 (674 patients aged 12 and over with non-segmental vitiligo covering 10% or less of the body), 1.5% ruxolitinib cream or an inactive cream was applied twice daily for 24 weeks. At least 75% improvement in the facial vitiligo score was reached by 29.8% and 30.9% of the ruxolitinib groups, versus 7.4% and 11.4% of the inactive-cream groups. The most common side effects were acne and itching where the cream was applied, and the authors noted that larger and longer trials are needed to judge its effect and safety.

For an updated comprehensive treatment review including JAK inhibitors and other recent additions, see our Vitiligo page.

Back to Table of Contents

Combination Protocols and Adjunct Nutrients

A comprehensive nutritional adjunct protocol alongside phenylalanine + ultraviolet A for vitiligo includes attention to several other deficiencies and antioxidant systems:

The nutritional adjunct approach is unlikely to produce dramatic repigmentation by itself but appears to support response rates and reduce relapse when combined with standard phototherapy and topical treatments.

What a 2021 systematic review found. A systematic review of diet, supplement and herbal add-on treatments for vitiligo (Shakhbazova and colleagues, 2021) examined 26 studies. It named three as the most promising: oral phenylalanine added to ultraviolet A therapy, oral Ginkgo biloba on its own, and oral Polypodium leucotomos with light therapy. The reviewers called the growing evidence promising but said more studies are needed.

Back to Table of Contents

PKU and the Lighter Pigmentation Connection

The connection between phenylalanine metabolism and skin pigmentation is dramatically visible in untreated phenylketonuria. PKU patients lack functional phenylalanine hydroxylase and cannot efficiently convert phenylalanine to tyrosine. The downstream consequence is reduced tyrosine availability for both catecholamine and melanin synthesis. Untreated PKU patients characteristically have:

The mechanism is straightforward: even though dietary phenylalanine intake may be adequate, the absent phenylalanine hydroxylase prevents conversion to tyrosine, and the resulting tyrosine deficit limits melanin synthesis. The simultaneous accumulation of phenylalanine itself may further inhibit melanin synthesis through direct competitive inhibition of tyrosinase, since phenylalanine and tyrosine have similar structures.

The PKU pigmentation phenotype is reversible (at least in part) by dietary tyrosine supplementation in PKU patients, which can produce darkening of hair and skin. This provides indirect confirmation that the pigmentation defect is substrate-limited rather than melanocyte-intrinsic.

Phenylalanine handling in vitiligo itself. A 1998 study (Schallreuter and colleagues) measured phenylalanine in the skin of 23 people with vitiligo and found higher levels in the white patches than in normal skin of the same person in every case. After a single oral dose of L-phenylalanine (100 mg/kg body weight) in 32 patients, all showed slower conversion of phenylalanine to tyrosine, and in 41% the conversion was significantly slower. None had raised blood phenylalanine without the test dose.

The PKU connection has two practical implications for the phenylalanine and vitiligo discussion:

  1. It validates the substrate hypothesis — melanin synthesis is indeed limited by phenylalanine/tyrosine availability under sufficient deficiency
  2. It confirms the absolute contraindication of phenylalanine supplementation in PKU. Even for vitiligo treatment, tyrosine, not phenylalanine, is the substrate that bypasses the missing enzyme in PKU

Back to Table of Contents

Cautions and Contraindications

The phenylalanine + ultraviolet A approach to vitiligo is generally safe when used by patients without these contraindications and when the ultraviolet A exposure is controlled and progressive. Patient adherence over the required 12 to 18 month treatment course is the main practical limitation.

Back to Table of Contents

Key Research Papers

  1. Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB (1985). Phenylalanine and UVA light for the treatment of vitiligo. Archives of Dermatological Research, 277(2):126-30. — PubMed PMID: 3885873
  2. Antoniou C et al. (1989). Vitiligo therapy with oral and topical phenylalanine with UVA exposure. International Journal of Dermatology, 28(8):545-7. — PubMed PMID: 2583897
  3. Schulpis CH et al. (1989). Phenylalanine plus ultraviolet light: Preliminary report of a promising treatment for childhood vitiligo. Pediatric Dermatology, 6(4):332-5. — PubMed PMID: 2616391
  4. Siddiqui AH et al. (1994). L-Phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology, 188(3):215-8. — PubMed PMID: 8186511
  5. Camacho F, Mazuecos J (1999). Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Archives of Dermatology. — PubMed PMID: 10052421
  6. Greiner D, Ochsendorf FR, Milbradt R (1994). Vitiligo therapy with phenylalanine/UV A. Catamnestic studies after five years [article in German]. Hautarzt, 45(7):460-3. — PubMed PMID: 7928339
  7. Juhlin L, Olsson MJ (1997). Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Dermato-Venereologica. — PubMed PMID: 9394983
  8. Schallreuter KU et al. (1998). In vivo evidence for compromised phenylalanine metabolism in vitiligo. Biochemical and Biophysical Research Communications, 243(2):395-9. — PubMed PMID: 9480820
  9. Ortonne JP, MacDonald DM, Micoud A, Thivolet J (1979). PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. British Journal of Dermatology, 101(1):1-12. — PubMed PMID: 113025
  10. Le Poole IC et al. (1993). Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation. Journal of Investigative Dermatology. — PubMed PMID: 7684427
  11. Ezzedine K et al. (2015). Vitiligo. The Lancet, 386(9988):74-84. — PubMed PMID: 25596811
  12. Picardo M et al. (2015). Vitiligo. Nature Reviews Disease Primers. — PubMed PMID: 27189851
  13. Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004). Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological Reviews, 84(4):1155-228. — PubMed PMID: 15383650
  14. Rosmarin D et al. (2022). Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine, 387(16):1445-1455. — PubMed PMID: 36260792
  15. Shakhbazova A, Wu H, Chambers CJ, Sivamani RK (2021). A Systematic Review of Nutrition, Supplement, and Herbal-Based Adjunctive Therapies for Vitiligo. Journal of Alternative and Complementary Medicine, 27(4):294-311. — PubMed PMID: 33337930

PubMed Topic Searches

  1. PubMed: Phenylalanine vitiligo UVA
  2. PubMed: Tyrosinase melanin synthesis
  3. PubMed: Vitiligo autoimmunity
  4. PubMed: Khellin KUVA vitiligo
  5. PubMed: Narrowband UVB vitiligo

Back to Table of Contents

Connections

Back to Table of Contents